We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$435M
AUM Growth
+$106M
Cap. Flow
+$33.1M
Cap. Flow %
7.6%
Top 10 Hldgs %
83.67%
Holding
29
New
6
Increased
6
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$51.9M
2
UTHR icon
United Therapeutics
UTHR
+$41.1M
3
MRK icon
Merck
MRK
+$36.8M
4
VERA icon
Vera Therapeutics
VERA
+$18M
5
AXSM icon
Axsome Therapeutics
AXSM
+$15.1M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$29.2M
3
VRNA
Verona Pharma
VRNA
+$20.5M
4
INSP icon
Inspire Medical Systems
INSP
+$19.4M
5
UNH icon
UnitedHealth
UNH
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$609B
$56.2M 12.91%
+302,831
New +$51.9M
UTHR icon
2
United Therapeutics
UTHR
$22.7B
$51.2M 11.77%
+122,187
New +$41.1M
MRK icon
3
Merck
MRK
$315B
$37.5M 8.62%
+446,874
New +$36.8M
AXSM icon
4
Axsome Therapeutics
AXSM
$11.8B
$35.5M 8.16%
292,137
+134,276
+85% +$15.1M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$34.8M 7.99%
174,829
+27,187
+18% +$5.07M
VERA icon
6
Vera Therapeutics
VERA
$2.76B
$34.6M 7.95%
1,190,207
+777,093
+188% +$18M
ARGX icon
7
argenx
ARGX
$53.8B
$32M 7.36%
43,411
-4,382
-9% -$2.89M
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$12.8B
$31.1M 7.14%
67,706
-30,059
-31% -$11.2M
SLNO
9
DELISTED
Soleno Therapeutics
SLNO
$30.5M 7%
450,585
+161,705
+56% +$12M
ABBV icon
10
AbbVie
ABBV
$450B
$20.8M 4.77%
89,621
+33,960
+61% +$6.92M
KRRO icon
11
Korro Bio
KRRO
$177M
$16.2M 3.72%
337,764
+198,271
+142% +$4.4M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.6B
$14.7M 3.38%
+366,102
New +$12.9M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$11.1M 2.54%
724,859
-289,597
-29% -$3.77M
STVN icon
14
Stevanato
STVN
$5.23B
$8.57M 1.97%
+332,912
New +$8.22M
DNTH icon
15
Dianthus Therapeutics
DNTH
$5.77B
$7.2M 1.65%
+182,867
New +$4.67M
TARS icon
16
Tarsus Pharmaceuticals
TARS
$2.61B
$7.09M 1.63%
119,260
-58,396
-33% -$2.87M
PRAX icon
17
Praxis Precision Medicines
PRAX
$8.77B
$4.03M 0.93%
75,986
-119,446
-61% -$5.79M
BHVN icon
18
Biohaven
BHVN
$2.32B
$2.24M 0.51%
149,179
-122,188
-45% -$1.78M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-89,525
Closed -$29.2M
EOLS icon
20
Evolus
EOLS
$377M
– –
-1,239,031
Closed -$11.4M
FEMY icon
21
Femasys
FEMY
$9.09M
– –
-1,530
Closed -$29.6K
INSP icon
22
Inspire Medical Systems
INSP
$1.46B
– –
-149,244
Closed -$19.4M
ISRG icon
23
Intuitive Surgical
ISRG
$122B
– –
-12,824
Closed -$6.97M
LEGN icon
24
Legend Biotech
LEGN
$4.31B
– –
-173,260
Closed -$6.15M
NUVL
25
DELISTED
Nuvalent
NUVL
– –
-75,973
Closed -$5.8M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Tri Locum Partners held 29 positions worth $435M, up 32% from $330M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Tri Locum Partners deployed $33.1M of net new capital in Q3 2025, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was Johnson & Johnson: 302,831 shares worth $56.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $11.2M trimmed.

  • Tri Locum Partners's largest Q3 2025 buy was Johnson & Johnson: 302,831 shares worth $56.2M.
  • Tri Locum Partners added most to Vera Therapeutics in Q3 2025, an estimated $18M increase.
  • Tri Locum Partners's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $11.2M.
  • Tri Locum Partners fully exited Teva Pharmaceuticals in Q3 2025, selling an estimated $34.3M.
  • Tri Locum Partners's ten largest holdings make up 84% of its $435M portfolio in Q3 2025.
  • Tri Locum Partners opened 6 new positions and closed 11 in Q3 2025.
  • Tri Locum Partners's portfolio value rose 32% quarter-over-quarter to $435M.

Based on Tri Locum Partners's 13F filing for Q3 2025, filed 14 Nov 2025.